BlossomHill Therapeutics (BLSM) vs Monopar Therapeutics (MNPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Monopar Therapeutics is the larger company by market cap ($549.1 million vs $522.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLSM | MNPR |
|---|---|---|
| Share price | $16.45 | $81.81 |
| Market cap | $522.86M | $549.12M |
| 1-day change | -0.96% | -2.35% |
| YTD return | — | +28.30% |
| 1-year return | — | -14.96% |
| 5-year return | — | +241.26% |
| EPS (TTM) | $-4.70 | $-2.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.99 | $124.82 |
| 52-week low | $15.25 | $50.07 |
| Distance from 52-week high | -41.23% | -34.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +115.20% | +58.81% |
| Average volume | 263.46K | 215.52K |
| Shares outstanding | 31.78M | 6.71M |
| Employees | 69 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
BLSM vs MNPR FAQ
Which is bigger, BlossomHill Therapeutics or Monopar Therapeutics?
Monopar Therapeutics (MNPR) is larger, with a market capitalization of $549.12M compared with $522.86M for BlossomHill Therapeutics (BLSM).
Are BlossomHill Therapeutics and Monopar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.